FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1488-1490 October 7, 2004 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Tannock, I. F. Related Article by Petrylak, D. P. PubMed Citation

Prostate cancer is the second-leading cause of cancer-related death among men and the seventh most common cause of death in the United States overall. Most prostate cancers are androgen-dependent, meaning that they respond to androgen-ablation therapy. However, these tumors eventually become androgen-independent and grow despite androgen ablation. When prostate cancer is localized in the prostate, the treatment of choice is prostatectomy or irradiation. However, when the tumor relapses or is already metastatic at diagnosis, therapy is problematic. Androgen ablation has been the main option for unconfined disease for more than 50 years, since Clarence V. Hodges and Charles B. Huggins . . . [Full Text of this Article]

Source Information

From the Departments of Urology and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minn.

This article has been cited by other articles:

• Nabhan, C. (2008). Is Chemotherapy the Standard for Asymptomatic Androgen-Independent Prostate Cancer?. JCO 26: 2413-2414 [Full Text]  
• Sanders, T., Harrison, S., Checkland, K. (2008). Evidence-based medicine and patient choice: the case of heart failure care. J Health Serv Res Policy 13: 103-108 [Abstract] [Full Text]  
• Hara, T., Miyazaki, H., Lee, A., Tran, C. P., Reiter, R. E. (2008). Androgen Receptor and Invasion in Prostate Cancer. Cancer Res. 68: 1128-1135 [Abstract] [Full Text]  
• Schayowitz, A., Sabnis, G., Njar, V. C.O., Brodie, A. M.H. (2008). Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Molecular Cancer Therapeutics 7: 121-132 [Abstract] [Full Text]  
• Heemers, H. V., Tindall, D. J. (2007). Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex. Endocr. Rev. 28: 778-808 [Abstract] [Full Text]  
• Dehm, S. M., Tindall, D. J. (2007). Androgen Receptor Structural and Functional Elements: Role and Regulation in Prostate Cancer. Mol. Endocrinol. 21: 2855-2863 [Abstract] [Full Text]  
• Heemers, H. V., Regan, K. M., Dehm, S. M., Tindall, D. J. (2007). Androgen Induction of the Androgen Receptor Coactivator Four and a Half LIM Domain Protein-2: Evidence for a Role for Serum Response Factor in Prostate Cancer. Cancer Res. 67: 10592-10599 [Abstract] [Full Text]  
• Reiner, T., de las Pozas, A., Parrondo, R., Perez-Stable, C. (2007). Progression of Prostate Cancer from a Subset of p63-Positive Basal Epithelial Cells in FG/Tag Transgenic Mice. Mol Cancer Res 5: 1171-1179 [Abstract] [Full Text]  
• Dehm, S. M., Regan, K. M., Schmidt, L. J., Tindall, D. J. (2007). Selective Role of an NH2-Terminal WxxLF Motif for Aberrant Androgen Receptor Activation in Androgen Depletion Independent Prostate Cancer Cells. Cancer Res. 67: 10067-10077 [Abstract] [Full Text]  
• Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P. A., Sawyers, C. L., Wu, H. (2007). Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development. Cancer Res. 67: 6083-6091 [Abstract] [Full Text]  
• McDonald, R., Harrison, S., Checkland, K., Campbell, S. M, Roland, M. (2007). Impact of financial incentives on clinical autonomy and internal motivation in primary care: ethnographic study. BMJ 334: 1357-1357 [Abstract] [Full Text]  
• Tamura, K., Furihata, M., Tsunoda, T., Ashida, S., Takata, R., Obara, W., Yoshioka, H., Daigo, Y., Nasu, Y., Kumon, H., Konaka, H., Namiki, M., Tozawa, K., Kohri, K., Tanji, N., Yokoyama, M., Shimazui, T., Akaza, H., Mizutani, Y., Miki, T., Fujioka, T., Shuin, T., Nakamura, Y., Nakagawa, H. (2007). Molecular Features of Hormone-Refractory Prostate Cancer Cells by Genome-Wide Gene Expression Profiles. Cancer Res. 67: 5117-5125 [Abstract] [Full Text]  
• Yang, C.-C., Wang, Y.-C., Wei, S., Lin, L.-F., Chen, C.-S., Lee, C.-C., Lin, C.-C., Chen, C.-S. (2007). Peroxisome Proliferator-Activated Receptor {gamma}-Independent Suppression of Androgen Receptor Expression by Troglitazone Mechanism and Pharmacologic Exploitation. Cancer Res. 67: 3229-3238 [Abstract] [Full Text]  
• Heemers, H. V., Sebo, T. J., Debes, J. D., Regan, K. M., Raclaw, K. A., Murphy, L. M., Hobisch, A., Culig, Z., Tindall, D. J. (2007). Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells. Cancer Res. 67: 3422-3430 [Abstract] [Full Text]  
• Bonaccorsi, L., Nosi, D., Muratori, M., Formigli, L., Forti, G., Baldi, E. (2007). Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines. J Mol Endocrinol 38: 51-66 [Abstract] [Full Text]  
• Jia, L., Shen, H. C., Wantroba, M., Khalid, O., Liang, G., Wang, Q., Gentzschein, E., Pinski, J. K., Stanczyk, F. Z., Jones, P. A., Coetzee, G. A. (2006). Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells.. Mol. Cell. Biol. 26: 7331-7341 [Abstract] [Full Text]  
• Gao, H., Ouyang, X., Banach-Petrosky, W. A., Shen, M. M., Abate-Shen, C. (2006). Emergence of Androgen Independence at Early Stages of Prostate Cancer Progression in Nkx3.1; Pten Mice. Cancer Res. 66: 7929-7933 [Abstract] [Full Text]  
• Husbeck, B., Bhattacharyya, R. S., Feldman, D., Knox, S. J. (2006). Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action.. Molecular Cancer Therapeutics 5: 2078-2085 [Abstract] [Full Text]  
• MORETTI, C., MAMMI, C., FRAJESE, G. V., MARIANI, S., GNESSI, L., ARIZZI, M., WANNENES, F., FRAJESE, G. (2006). PACAP and Type I PACAP Receptors in Human Prostate Cancer Tissue. Ann. N. Y. Acad. Sci. 1070: 440-449 [Abstract] [Full Text]  
• Rosenfeld, M. G., Lunyak, V. V., Glass, C. K. (2006). Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 20: 1405-1428 [Abstract] [Full Text]  
• Wallner, L., Dai, J., Escara-Wilke, J., Zhang, J., Yao, Z., Lu, Y., Trikha, M., Nemeth, J. A., Zaki, M. H., Keller, E. T. (2006). Inhibition of Interleukin-6 with CNTO328, an Anti-Interleukin-6 Monoclonal Antibody, Inhibits Conversion of Androgen-Dependent Prostate Cancer to an Androgen-Independent Phenotype in Orchiectomized Mice.. Cancer Res. 66: 3087-3095 [Abstract] [Full Text]  
• Pienta, K. J., Bradley, D. (2006). Mechanisms underlying the development of androgen-independent prostate cancer.. Clin. Cancer Res. 12: 1665-1671 [Full Text]  
• Gleave, M., Kelly, W. K. (2005). High-Risk Localized Prostate Cancer: A Case for Early Chemotherapy. JCO 23: 8186-8191 [Abstract] [Full Text]  
• Bhandari, M. S., Crook, J., Hussain, M. (2005). Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice?. JCO 23: 8212-8218 [Abstract] [Full Text]  
• Pienta, K. J., Smith, D. C. (2005). Advances in Prostate Cancer Chemotherapy: A New Era Begins. CA Cancer J Clin 55: 300-318 [Abstract] [Full Text]  
• Suriano, R., Ghosh, S. K., Ashok, B. T., Mittelman, A., Chen, Y., Banerjee, A., Tiwari, R. K. (2005). Differences in Glycosylation Patterns of Heat Shock Protein, gp96: Implications for Prostate Cancer Prevention. Cancer Res. 65: 6466-6475 [Abstract] [Full Text]  
• Stewart, J. R., O'Brian, C. A. (2005). Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells. Molecular Cancer Therapeutics 4: 726-732 [Abstract] [Full Text]